HEALTHglobal
Rhythm obesity drug wins broader use from FDA
Single source
Updated 3 hours ago
First seen March 20, 2026 18:31:54Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.